Sign in
CompletedPhase 2

Study Assessing Efficacy and Safety of NFL-101 as a Tobacco Cessation Therapy

Key facts

Who runs it
NFL Biosciences SAS
Where
France9 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
318 people enrolled
Started
12 Apr 2021
Ended
12 Apr 2024
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • NFL-101 dose 1
  • NFL-101 dose 2
  • Placebo
Record updated
19 June 2025

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Male or female subject ≥ 18 and ≤ 70-year-old
  • With ECOG/WHO performance status 0-1 (Appendix 1)
  • Subject currently smoking at least 11 cigarettes per day and with a dependency level ≥ 3 according to Fagerström Test for Nicotine Dependence scoring (see Appendix 2) [1]
  • Subject willing to quit smoking
  • Good general health (i.e. no uncontrolled medical condition, or no medical condition that could interfere with the conduct and the outcomes of the study, according to the investigator)
  • Good mental health (i.e. no alcohol or drug abuse in the past year, no psychiatric history- adequately treated depression is accepted)
  • For women of childbearing potential: commitment to consistently and correctly use of a highly effective contraceptive measure: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomised partner or sexual abstinence for the duration of the trial; (Females of non-childbearing potential: either surgically sterilized or at least 1 year postmenopausal (amenorrhoea duration at least 12 months))
  • Negative pregnancy test at screening visit
  • Laboratory parameters within the normal range of the laboratory (hematological, blood chemistry tests). Individual values out of the normal range can be accepted if judged clinically non relevant by the Investigator
  • Normal ECG recording on a 12-lead ECG at the screening visit:; 120 < PR < 210 ms,; QRS < 120 ms,; QTcf ≤ 430 ms for male and < 450 ms for female,; No sign of any trouble of sinusal automatism,; Or considered NCs by investigators
  • Negative prick test at screening visit for the whole study product (extract of Tobacco leaf and NaCL), and positive for histamine
  • French speaking subject
  • Covered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research
  • Subject having signed the informed consent agreement

Who cannot take part

  • Concomitant participation to another clinical trial
  • Concomitant active infectious diseases
  • Concomitant use of treatment known to interfere with immune response (not including desensitization therapies)
  • Prior exposure to a nicotine vaccine or to any other vaccine within 30 days before study product administration
  • Concomitant use (and within previous 60 days) of any smoking cessation therapy (including electronic cigarettes and alternative methods such as hypnosis or acupuncture)
  • Uncontrolled diabetes
  • Pregnancy and breastfeeding
  • Legal incapacity or physical, psychological or mental status interfering with the subject's ability to sign the informed consent or to terminate the study
  • Subject who would receive more than 4500 euros as indemnities for his participation in biomedical research within the 12 last months, including the indemnities for the present study Subject who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

CESTO 2 is a 318 participants, 3-arm, multicentric, randomized, double-blind, placebo-controlled Phase II clinical trial.

Read full original descriptionShow less

The main objectives are to select the most efficient dose and to assess long-term efficacy of NFL-101 compared to placebo, for abrupt cessation and for reduction before cessation.

The 3 groups in the trial

  • NFL-101 Dose 1Treatment being tested

    50 µg per injection (in each arm), two injections at day 1, two injections at day 8, optional injections later on

  • NFL-101 Dose 2Treatment being tested

    100 µg per injection (in each arm), two injections at day 1, two injections at day 8, optional injections later on

  • PlaceboPlacebo, for comparison

    The placebo will consist of two syringes containing 1 mL of dilution solution, two injections at day 1, two injections at day 8, optional injections later on

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Record updated
19 June 2025